Iovance Biotherapeutics, Inc.
IOVA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,145 | $1,912 | $1,018 | $2,929 |
| - Cash | $116 | $115 | $232 | $78 |
| + Debt | $58 | $76 | $85 | $72 |
| Enterprise Value | $2,088 | $1,873 | $871 | $2,922 |
| Revenue | $164 | $1 | $0 | $0 |
| % Growth | 13,699% | – | – | – |
| Gross Profit | $40 | -$10 | $0 | $0 |
| % Margin | 24.4% | -804.5% | – | – |
| EBITDA | -$352 | -$427 | -$378 | -$329 |
| % Margin | -214.3% | -35,948.9% | – | – |
| Net Income | -$372 | -$444 | -$396 | -$342 |
| % Margin | -226.8% | -37,345.4% | – | – |
| EPS Diluted | -1.28 | -1.89 | -2.49 | -2.23 |
| % Growth | 32.3% | 24.1% | -11.7% | – |
| Operating Cash Flow | -$353 | -$362 | -$293 | -$228 |
| Capital Expenditures | -$11 | -$22 | -$20 | -$38 |
| Free Cash Flow | -$364 | -$384 | -$313 | -$266 |